Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on February 28, 2022, at 4:30 p.m. ET. This event will report the fourth-quarter and full-year financial results for 2021, and provide a business update. Atea, focused on developing oral therapies for severe viral diseases, aims to address unmet medical needs, particularly for infections like COVID-19 and hepatitis C. Following the live call, an archived version will be accessible on the company’s website.

Positive

• Focus on discovering and developing oral therapies for life-threatening viral diseases.
• Development of potent, selective nucleotide prodrugs targeting difficult-to-treat infections.

Negative

• None.

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business update.

To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 7171208. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company's website, www.ateapharma.com. An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus (HCV), dengue virus and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

FAQ

What is the date of Atea Pharmaceuticals' next conference call?

Atea Pharmaceuticals' next conference call is scheduled for February 28, 2022.

What will Atea Pharmaceuticals report during the conference call?

Atea Pharmaceuticals will report its financial results for the fourth quarter and full-year ended December 31, 2021, and provide a business update.

What is the stock symbol for Atea Pharmaceuticals?

The stock symbol for Atea Pharmaceuticals is AVIR.

How can I access the Atea Pharmaceuticals conference call?

To access the conference call, dial (833) 301-1150 domestically or (914) 987-7391 internationally, five minutes prior to the start time.